Tivdak® is a type of medicine called an antibody-drug conjugate (ADC), which is thought to work by attaching to a protein found on certain types of cancer cells. It has been approved by the United States Food and Drug Administration (FDA) to treat adults with cervical cancer that has returned or has spread to other parts of the body, and who have received chemotherapy that did not work or is no longer working.
In a previous phase 3 study (innovaTV 301), patients with recurrent or metastatic cervical cancer who received Tivdak® lived longer than those who received chemotherapy.1
For more information about Tivdak®, including previous clinical trial results and safety information, visit Tivdak.com.
1. Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301). ClinicalTrials.gov identifier: NCT04697628. Updated March 12, 2025. Accessed April 8, 2025. https://clinicaltrials.gov/study/NCT04697628